CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCE
The present invention relates to crystalline forms of N-[4-[4- (4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4- [[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2- pyridinecarboxamide (formula (I)). The compound of formula (I) is an irreversible menin-MLL inhibitor for use in the...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HE, HONGYAN TAN, HEOW LAW, BRIAN LU, DANIEL WONG, ANGELINA SAU MAN SOMANATH, PRIYANKA PALMER, JAMES T LIN, NAN-HORNG KINOSHITA, TAISEI BUTLER, THOMAS JAING, SIYI |
| description | The present invention relates to crystalline forms of N-[4-[4- (4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4- [[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2- pyridinecarboxamide (formula (I)). The compound of formula (I) is an irreversible menin-MLL inhibitor for use in the treatment of e.g. cancer, including e.g. lymphoma and leukemia, and autoimmune diseases. The present invention discloses the characterisation of crystalline forms by e.g. XRPD, FTIR, DSC and TGA as well as pharmacological data.
La présente invention concerne des formes cristallines de N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-D]pyrimidine-6-yl]phényl]-4-[[3(R)-[(1-oxo-2-propène-1-yl)amino]-1-pipéridinyl]méthyl]-2-pyridinecarboxamide (formule (I). Le composé (I) est un inhibiteur irréversible de ménine-MLL pour une utilisation dans le traitement par ex. du cancer, par ex. d'un lymphome, d'une leucémie et de maladies auto-immunes.L'invention concerne également la caractérisation de formes cristallines par ex. par XRPD, FTIR, DSC et TGA ainsi que des données pharmacologiques. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3229150A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3229150A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3229150A13</originalsourceid><addsrcrecordid>eNqNj89KxDAQxvfiQdR3yLGFHbDtruIxTadkIMmE2SBbSlkWqSfRhfWZfQ4T8AGEgfn3-_hmbjc_RqZD0s5RQDWyeMWjCjDvSlQ78CzRct5OroZnC3ESYcdzu-1gWHJHngYK8ASTW6LFzC2QxXNXSQ1z1QAfWUELUThigCZztfYUeMl1pIhS9FnlMdkibotHmaHR0vMxwwNulQ6KRPAV5UC9Q-UxZFvvnKJgqafEUu5XyaJKgjplIJVnjA4G7zc37-eP6_rwl-82asRkLKyXr9N6vZzf1s_1-2R017Yvzf5RN90_kF_wqVcv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCE</title><source>esp@cenet</source><creator>HE, HONGYAN ; TAN, HEOW ; LAW, BRIAN ; LU, DANIEL ; WONG, ANGELINA SAU MAN ; SOMANATH, PRIYANKA ; PALMER, JAMES T ; LIN, NAN-HORNG ; KINOSHITA, TAISEI ; BUTLER, THOMAS ; JAING, SIYI</creator><creatorcontrib>HE, HONGYAN ; TAN, HEOW ; LAW, BRIAN ; LU, DANIEL ; WONG, ANGELINA SAU MAN ; SOMANATH, PRIYANKA ; PALMER, JAMES T ; LIN, NAN-HORNG ; KINOSHITA, TAISEI ; BUTLER, THOMAS ; JAING, SIYI</creatorcontrib><description>The present invention relates to crystalline forms of N-[4-[4- (4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4- [[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2- pyridinecarboxamide (formula (I)). The compound of formula (I) is an irreversible menin-MLL inhibitor for use in the treatment of e.g. cancer, including e.g. lymphoma and leukemia, and autoimmune diseases. The present invention discloses the characterisation of crystalline forms by e.g. XRPD, FTIR, DSC and TGA as well as pharmacological data.
La présente invention concerne des formes cristallines de N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-D]pyrimidine-6-yl]phényl]-4-[[3(R)-[(1-oxo-2-propène-1-yl)amino]-1-pipéridinyl]méthyl]-2-pyridinecarboxamide (formule (I). Le composé (I) est un inhibiteur irréversible de ménine-MLL pour une utilisation dans le traitement par ex. du cancer, par ex. d'un lymphome, d'une leucémie et de maladies auto-immunes.L'invention concerne également la caractérisation de formes cristallines par ex. par XRPD, FTIR, DSC et TGA ainsi que des données pharmacologiques.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230223&DB=EPODOC&CC=CA&NR=3229150A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25566,76549</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230223&DB=EPODOC&CC=CA&NR=3229150A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HE, HONGYAN</creatorcontrib><creatorcontrib>TAN, HEOW</creatorcontrib><creatorcontrib>LAW, BRIAN</creatorcontrib><creatorcontrib>LU, DANIEL</creatorcontrib><creatorcontrib>WONG, ANGELINA SAU MAN</creatorcontrib><creatorcontrib>SOMANATH, PRIYANKA</creatorcontrib><creatorcontrib>PALMER, JAMES T</creatorcontrib><creatorcontrib>LIN, NAN-HORNG</creatorcontrib><creatorcontrib>KINOSHITA, TAISEI</creatorcontrib><creatorcontrib>BUTLER, THOMAS</creatorcontrib><creatorcontrib>JAING, SIYI</creatorcontrib><title>CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCE</title><description>The present invention relates to crystalline forms of N-[4-[4- (4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4- [[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2- pyridinecarboxamide (formula (I)). The compound of formula (I) is an irreversible menin-MLL inhibitor for use in the treatment of e.g. cancer, including e.g. lymphoma and leukemia, and autoimmune diseases. The present invention discloses the characterisation of crystalline forms by e.g. XRPD, FTIR, DSC and TGA as well as pharmacological data.
La présente invention concerne des formes cristallines de N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-D]pyrimidine-6-yl]phényl]-4-[[3(R)-[(1-oxo-2-propène-1-yl)amino]-1-pipéridinyl]méthyl]-2-pyridinecarboxamide (formule (I). Le composé (I) est un inhibiteur irréversible de ménine-MLL pour une utilisation dans le traitement par ex. du cancer, par ex. d'un lymphome, d'une leucémie et de maladies auto-immunes.L'invention concerne également la caractérisation de formes cristallines par ex. par XRPD, FTIR, DSC et TGA ainsi que des données pharmacologiques.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNj89KxDAQxvfiQdR3yLGFHbDtruIxTadkIMmE2SBbSlkWqSfRhfWZfQ4T8AGEgfn3-_hmbjc_RqZD0s5RQDWyeMWjCjDvSlQ78CzRct5OroZnC3ESYcdzu-1gWHJHngYK8ASTW6LFzC2QxXNXSQ1z1QAfWUELUThigCZztfYUeMl1pIhS9FnlMdkibotHmaHR0vMxwwNulQ6KRPAV5UC9Q-UxZFvvnKJgqafEUu5XyaJKgjplIJVnjA4G7zc37-eP6_rwl-82asRkLKyXr9N6vZzf1s_1-2R017Yvzf5RN90_kF_wqVcv</recordid><startdate>20230223</startdate><enddate>20230223</enddate><creator>HE, HONGYAN</creator><creator>TAN, HEOW</creator><creator>LAW, BRIAN</creator><creator>LU, DANIEL</creator><creator>WONG, ANGELINA SAU MAN</creator><creator>SOMANATH, PRIYANKA</creator><creator>PALMER, JAMES T</creator><creator>LIN, NAN-HORNG</creator><creator>KINOSHITA, TAISEI</creator><creator>BUTLER, THOMAS</creator><creator>JAING, SIYI</creator><scope>EVB</scope></search><sort><creationdate>20230223</creationdate><title>CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCE</title><author>HE, HONGYAN ; TAN, HEOW ; LAW, BRIAN ; LU, DANIEL ; WONG, ANGELINA SAU MAN ; SOMANATH, PRIYANKA ; PALMER, JAMES T ; LIN, NAN-HORNG ; KINOSHITA, TAISEI ; BUTLER, THOMAS ; JAING, SIYI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3229150A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HE, HONGYAN</creatorcontrib><creatorcontrib>TAN, HEOW</creatorcontrib><creatorcontrib>LAW, BRIAN</creatorcontrib><creatorcontrib>LU, DANIEL</creatorcontrib><creatorcontrib>WONG, ANGELINA SAU MAN</creatorcontrib><creatorcontrib>SOMANATH, PRIYANKA</creatorcontrib><creatorcontrib>PALMER, JAMES T</creatorcontrib><creatorcontrib>LIN, NAN-HORNG</creatorcontrib><creatorcontrib>KINOSHITA, TAISEI</creatorcontrib><creatorcontrib>BUTLER, THOMAS</creatorcontrib><creatorcontrib>JAING, SIYI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HE, HONGYAN</au><au>TAN, HEOW</au><au>LAW, BRIAN</au><au>LU, DANIEL</au><au>WONG, ANGELINA SAU MAN</au><au>SOMANATH, PRIYANKA</au><au>PALMER, JAMES T</au><au>LIN, NAN-HORNG</au><au>KINOSHITA, TAISEI</au><au>BUTLER, THOMAS</au><au>JAING, SIYI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCE</title><date>2023-02-23</date><risdate>2023</risdate><abstract>The present invention relates to crystalline forms of N-[4-[4- (4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4- [[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2- pyridinecarboxamide (formula (I)). The compound of formula (I) is an irreversible menin-MLL inhibitor for use in the treatment of e.g. cancer, including e.g. lymphoma and leukemia, and autoimmune diseases. The present invention discloses the characterisation of crystalline forms by e.g. XRPD, FTIR, DSC and TGA as well as pharmacological data.
La présente invention concerne des formes cristallines de N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-D]pyrimidine-6-yl]phényl]-4-[[3(R)-[(1-oxo-2-propène-1-yl)amino]-1-pipéridinyl]méthyl]-2-pyridinecarboxamide (formule (I). Le composé (I) est un inhibiteur irréversible de ménine-MLL pour une utilisation dans le traitement par ex. du cancer, par ex. d'un lymphome, d'une leucémie et de maladies auto-immunes.L'invention concerne également la caractérisation de formes cristallines par ex. par XRPD, FTIR, DSC et TGA ainsi que des données pharmacologiques.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3229150A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T09%3A07%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HE,%20HONGYAN&rft.date=2023-02-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3229150A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |